BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier

Rhea-AI Summary

BioStem Technologies (BSEM) has added its VENDAJE® and VENDAJE AC® placental-derived wound care allografts to existing contracts with Vizient and Premier, two of the largest U.S. Group Purchasing Organizations, making both products available for hospital ordering effective immediately.

This marks the first GPO contract coverage for VENDAJE and VENDAJE AC and extends BioStem’s hospital channel for its BioRetain® wound care line. Vizient serves more than 5,000 hospitals and Premier more than 4,000. Both products are minimally manipulated dehydrated tissue allografts manufactured using BioStem’s proprietary BioRetain process.

Positive

• First GPO coverage for VENDAJE and VENDAJE AC via Vizient and Premier contracts, immediately opening access across thousands of member hospitals.
• Expanded hospital channel for the BioRetain® wound care line by leveraging existing Vizient and Premier relationships that reach over 9,000 U.S. hospitals combined.

Negative

• None.

Market Context

The July 10 Form 10 announcement was followed by a 14.74% 24-hour gain, while the August 14 conferen...

Analysis

The July 10 Form 10 announcement was followed by a 14.74% 24-hour gain, while the August 14 conference notice preceded a -6.54% move. Against that mixed history, GPO access adds distribution context; hospital revenue conversion remains unverified.

Key Figures

GPO contracts: 2 contracts Vizient affiliated hospitals: more than 5,000 hospitals Premier affiliated hospitals: more than 4,000 hospitals

3 metrics

GPO contracts 2 contracts Vizient and Premier

Vizient affiliated hospitals more than 5,000 hospitals Hospitals served by Vizient

Premier affiliated hospitals more than 4,000 hospitals Hospitals served by Premier

Historical Context

5 past events · Latest: Aug 14 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 14	Conference presentation	Neutral	-6.5%	Management presentation announced; shares declined 6.54% over 24 hours.
Aug 12	Q2 earnings report	Negative	-18.4%	Revenue declined year over year amid net and adjusted EBITDA losses.
Aug 06	Nasdaq uplisting	Positive	+1.8%	Nasdaq Capital Market listing approved; trading began under unchanged ticker.
Jul 29	Earnings call scheduling	Neutral	-2.4%	Second-quarter results release and conference call scheduled for August 12.
Jul 10	Form 10 filing	Positive	+14.7%	Exchange Act registration filed while Nasdaq listing plans were reaffirmed.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Reactions were mixed: three of five selected events aligned with their categorized sentiment, while two neutral notices saw negative moves.

Key Terms

group purchasing organizations, perinatal tissue allograft, dehydrated tissue allografts, current good tissue practices, +1 more

5 terms

group purchasing organizations financial

"two of the nation's largest Group Purchasing Organizations (GPOs)."

Group purchasing organizations are companies that negotiate bulk buying deals on behalf of a group of members—such as hospitals, clinics or other businesses—so members pay lower prices for supplies and services. For investors, GPOs matter because they influence cost structures and margins for their member buyers and suppliers: stronger GPO contracts can drive steady fee-based revenue for the GPO and shift pricing and sales volumes across connected suppliers, similar to a neighborhood buying club leveraging volume for discounts.

perinatal tissue allograft medical

"commercialization of perinatal tissue allograft products"

Perinatal tissue allograft is biological material taken from tissues associated with childbirth—such as placenta, umbilical cord, amniotic membrane or fluid—and processed from one human donor to be implanted or applied to a different patient. Think of it as donated birth-related tissue used like a spare part to support healing or tissue repair in another person. It matters to investors because these grafts are regulated medical products used in wound care, orthopedics and regenerative medicine, so their safety, supply chain, and regulatory status affect commercial prospects.

dehydrated tissue allografts medical

"multilayer allograft retaining the amnion, intermediate, and chorion layers."

Dehydrated tissue allografts are human donor tissues that have been processed, sterilized, and dried so they can be stored and later used in medical procedures to repair or replace damaged tissue. Because dehydration preserves the tissue and simplifies shipping and storage—similar to how drying food extends its shelf life—these products affect clinical supply chains, manufacturing processes, regulatory oversight, and reimbursement, all of which matter to investors evaluating companies that make or market them.

current good tissue practices regulatory

"compliance with current Good Tissue Practices ("cGTP")"

A set of regulatory quality and safety rules that govern how human cells, tissues, and related medical products are collected, processed, stored, and tracked to prevent contamination, disease transmission, and mix-ups. Think of it like food-safety rules for biological material: it requires documented procedures, staff training, facility controls, donor screening, and recordkeeping. Investors care because compliance affects whether products can be sold, how inspections and recalls play out, and the legal and operational risks for a maker of tissue-based therapies.

current good manufacturing practices regulatory

"and current Good Manufacturing Practices ("cGMP")."

Current good manufacturing practices (cGMPs) are the regulatory standards that govern how medicines, medical devices, and other regulated products must be made to ensure consistent safety, purity, and quality. Think of them as a strict recipe and kitchen rules—clean facilities, trained staff, documented steps, and quality checks—so each batch turns out the same. For investors, cGMP compliance reduces the risk of product recalls, regulatory fines, production shutdowns, and damage to long-term revenue and reputation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Additions extend BioStem's hospital channel to its BioRetain® wound care line

POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation's largest Group Purchasing Organizations (GPOs). The products are available for order under both contracts effective immediately, marking the first GPO contract coverage for VENDAJE and VENDAJE AC.

"Opening hospital access for VENDAJE and VENDAJE AC is a significant step in expanding patient access to BioStem's BioRetain® wound care solutions," said Jason Matuszewski, Chief Executive Officer and Chairman of BioStem Technologies. "Clinicians in Vizient and Premier member hospitals can now reach for these products through their existing contracting channels, which removes a barrier that has limited where they could be used. These agreements position us to reach health systems and providers at scale and support the execution of our commercial strategy. We're pleased to build on our relationships with both organizations and to continue delivering value to hospitals, clinicians, and the patients they serve."

Vizient is the largest GPO in the United States by affiliated staffed beds, serving more than 5,000 hospitals, and Premier is the second largest, serving more than 4,000, according to figures published by the organizations.

VENDAJE® and VENDAJE AC® are placental-derived, minimally manipulated dehydrated tissue allografts that serve as a protective covering for soft tissue wounds. VENDAJE is composed of the amnion layer of the placental membrane. VENDAJE AC is a thicker, multilayer allograft retaining the amnion, intermediate, and chorion layers. Both products are manufactured using BioStem's proprietary BioRetain® process, which is designed to retain the native properties of placental tissue.

About BioStem Technologies, Inc. (Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain^®, CryoTek^® and SteriTek^® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox^®, Clarix^®, VENDAJE^® and American Amnion™ product lines.

Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.

Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342

Investor Relations:
Philip Trip Taylor, Gilmartin
ir@biostemtech.com

Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com

FAQ

What did BioStem Technologies (BSEM) announce about VENDAJE and VENDAJE AC?

BioStem Technologies announced that VENDAJE® and VENDAJE AC® have been added to its existing contracts with Vizient and Premier, providing the first GPO contract coverage for these products and making them available for hospital orders effective immediately.

How do the Vizient and Premier contracts affect hospital access to VENDAJE and VENDAJE AC for BSEM?

With VENDAJE and VENDAJE AC now on Vizient and Premier contracts, clinicians at member hospitals can order these products through existing purchasing channels, which the company says removes a prior barrier and broadens hospital access to its BioRetain® wound care solutions.

What kind of products are VENDAJE and VENDAJE AC from BioStem Technologies (BSEM)?

VENDAJE® and VENDAJE AC® are placental-derived, minimally manipulated dehydrated tissue allografts used as protective coverings for soft tissue wounds. VENDAJE uses the amnion layer, while VENDAJE AC is a thicker multilayer graft retaining amnion, intermediate, and chorion layers.

How many hospitals could potentially access VENDAJE products through Vizient and Premier for BSEM?

Vizient serves more than 5,000 hospitals and Premier serves more than 4,000 hospitals. By adding VENDAJE and VENDAJE AC to contracts with both GPOs, BioStem positions these products for potential use across a large national hospital network.

What technology does BioStem (BSEM) use to manufacture VENDAJE and VENDAJE AC?

VENDAJE and VENDAJE AC are manufactured using BioStem’s proprietary BioRetain® process, which is designed to retain the native properties of placental tissue for clinical use as wound coverings.